Semifinalist Teams Selected in $10M ANA Avatar XPRIZE Competition
5.4.2021 18:00:00 EEST | Business Wire | Press release
XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, announced today that 38 teams from 16 countries are advancing to the semifinals round of the $10M ANA Avatar XPRIZE competition.
Sponsored by All Nippon Airways (ANA), Japan’s largest airline, the Avatar XPRIZE is a four-year global competition focused on the development of an avatar system that will deploy a human’s senses, actions, and presence to a remote location in real time, leading to a more connected world. These avatars must demonstrate the ability to execute tasks across a variety of real-world scenarios and convey a sense of presence for both the operator and the recipient in those interactions. In the future, avatars could help provide critical care and deploy immediate responses in emergency situations, or offer opportunities for exploration and new ways of collaboration, stretching the boundaries of what is possible and maximizing the impact of skill and knowledge sharing.
“We are rapidly approaching an era where it will be possible for a doctor in New York to export their skillset virtually to respond to a natural disaster across the globe,” said Anousheh Ansari, CEO of XPRIZE. “The task at hand for these incredible semifinalist teams competing in the ANA Avatar XPRIZE is to break through physical limitations and expand the capacity of humankind itself through transformative robotic avatar technology.”
In February 2021, qualified teams completed their semifinalist selection submissions—the second round of technical submissions for evaluation by the judging panel. Each team submitted a comprehensive write-up detailing their avatar system's capabilities and their development plans, accompanied by a demonstration video showcasing their technology in action. The judges extensively reviewed the submissions and selected 38 semifinalists to advance out of the field of 77 qualified teams.
The ANA Avatar XPRIZE semifinalist teams are:
- 1to1Robotics, Hackensack, New Jersey, United States
- Aham, Bangalore, India
- Augnition, Helsinki, Finland
- AvaDynamics, Pittsburgh, Pennsylvania, United States
- Avatar Quest, San Jose, California, United States
- AVATRINA, Urbana, Illinois, United States
- BellContinuous, Arlington, Texas, United States
- Cyberselves, Sheffield, United Kingdom
- Dragon Tree Labs, Moscow, Russia
- ENZO AVATAR, Bucaramanga, Colombia
- Forged Droids, Tempe, Arizona, United States
- GITAI, Tokyo, Japan
- H2L, Tokyo, Japan
- Human Fusions, Cleveland, Ohio, United States
- i-Botics, Utrecht, Netherlands
- iCub, Genoa, Italy
- Inbiodroid, Irapuato, Mexico
- Janus, Tsukuba, Japan
- Junnichi Suko, Tokyo, Japan
- Kimaera Dynamics, Toronto, Canada
- Last Mile – small world project 2, Osaka, Japan
- Limitless, Lugano, Switzerland
- NimbRo, Bonn, Germany
- Pollen Robotics, Bordeaux, France
- proRobot, Vysoké Mýto, Czech Republic
- Rezilient, St. Louis, Missouri, United States
- Robot Guru (HoloSuit), Mysuru, India
- Robotics Services LLC, Providence, Rhode Island, United States
- Roboy, Munich, Germany
- Sant'Anna, Pisa, Italy
- SYNAPSE, Tokyo, Japan
- Team Northeastern, Boston, Massachusetts, United States
- Team SNU, Ulsan, South Korea
- Team UNIST, Seoul, South Korea
- Telexistence, Tokyo, Japan
- Touchlab, Edinburgh, United Kingdom
- Virtual Sapiens, Chennai, India
- X-Presence, Kobe, Japan
Additional details about all competing teams can be found here.
“The breakthroughs that will develop out of the ANA Avatar XPRIZE have the potential to entirely reimagine the human experience,” said David Locke, Executive Prize Director of ANA Avatar XPRIZE. "We’re thrilled to announce the semifinalist teams and are excited to put their technologies to the test, and experience their ability to transport our sense of presence, during semifinals testing this fall.”
"Now that the semifinalist teams have been chosen, we are one very important step closer to realizing our dream of revolutionizing human connection," said Mitsuo Tomita, Senior Vice President of Marketing at All Nippon Airways. "As a company whose mission it is to connect people, we are beyond excited to see the technology that will be developed by these 38 teams. We are eager to see the innovative ways in which the teams will light up our imaginations with visions of a future in which travel and human connection are limitless."
After the completion of semifinals testing in Fall 2021, up to 20 teams will equally split a Semifinals prize purse of $2M and move on to finals testing in Summer 2022. There, they will compete to win a share of the $8M finals prize purse.
The grand prize will be awarded in June 2022 after finals testing, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use case scenarios. The winning team will integrate multiple emerging technologies to develop a physical, nonautonomous avatar system with which an operator can see, hear, and interact within a remote environment in a manner that feels as if they are truly there.
The ANA Avatar Advisory Board has been integral in the competition since its launch in January 2019. The group consists of esteemed robotics experts, haptics inventors, psychology professors, top entertainment researchers, virtual world creators, computer vision dynamos and more. The full list of experts can be found below with additional information and bios available here.
For more information on the ANA Avatar XPRIZE, the semifinalist teams, and ANA, please visit avatar.xprize.org.
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1M Digital Learning Challenge. For more information, visit xprize.org.
ABOUT ANA
Founded more than 60 years ago in 1952 with just two helicopters, All Nippon Airways (ANA), has become the largest airline in Japan, serving 46 international destinations and 50 domestic destinations.
ANA HOLDINGS Inc. (ANAHD) was established in 2013 as the largest airline group holding company in Japan comprised of 78 companies including ANA and Peach Aviation Limited, the leading LCC in Japan. The 78 companies organized under the ANAHD umbrella operate in a diverse range of markets, including air transportation, travel services and trade, and retail embody ANAHD’s shared values of exceptional service, responsible corporate citizenship and investment in the communities where they operate.
ANA is a launch customer and the biggest operator of the Boeing 787 Dreamliner, making ANAHD the biggest Dreamliner owner in the world. A member of Star Alliance since 1999, ANA has Joint Venture agreements with United Airlines, Lufthansa Airlines, Swiss International Airlines, Austrian Airlines and Brussels Airlines– giving it a truly global presence.
Supplementing its operations in commercial aviation, ANAHD has led the development of the innovative haptic robotics program, through its avatarin Inc. company, and its involvement in space with its partnership with JAXA, and other space related companies such as Astroscale and PD Aerospace.
The airline’s legacy of superior service has helped it earn SKYTRAX’s respected 5-Star rating every year since 2013, making ANA the only Japanese airline to win this prestigious designation and for eight consecutive years. ANA also has been recognized by Air Transport World as “Airline of the Year” three times (2007, 2013 and 2018); it is one of a select few airlines to win this prestigious award multiple times.
For more information, please refer to the following link:
https://www.ana.co.jp/group/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005239/en/
Contact information
Caden Kinard, XPRIZE
caden.kinard@xprize.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
